DeliKet (Substudy of KetoNiFast Study ID 22-1398_1) (DeliKet)
Impact of Cyclic, Daytime Enteral Nutrition and Ketogenic Nighttime Fasting on the Incidence of Postoperative Delirium in Critically Ill Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sandra E Stoll, MD, assProf.
- Phone Number: 82054 +49221478
- Email: sandraemilystoll@googlemail.com
Study Contact Backup
- Name: Fabian Dusse, PD, MD
- Phone Number: 40806 +49221478
- Email: fabian.dusse@uk-koeln.de
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Admission to an ICU
- Start of enteral nutrition
Exclusion Criteria:
- Severe liver insufficiency / liver disease (Child Pugh > B or 7-9 points)
- Post total Pancreatectomy / Insulin-depending diabetes mellitus (IDDM)
- Pregnancy / Lactation
- Hemoglobin-concentration < 80g/l
- Severe metabolic disorder / severe autoimmune disease
- Refractory respiratory or metabolic acidosis
- Disorder of mitochondrial transportation of fatty acids
- Disorder of the oxidation of fatty acids
- Disorder of gluconeogenesis, der ketone body production or ketone body degradation
- Intermittent porphyria
- Severe arrhythmia / cardiomyopathy
- Contraindications against enteral nutrition
- Missing informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventional group: Cyclic enteral nutrition with ketogenic nighttime fasting
Interventional group: Cyclic enteral daytime nutrition (12 hours) with ketogenic nighttime fasting (12 hours) with supplementation of exogenous ketones (ß-hydroxybutyrate) in the Intensive Care Setting.
|
Nighttime fasting and ß-hydroxybutyrate supplementation
Other Names:
|
|
No Intervention: Control group: Conventional continuous enteral nutrition
Continuous (24 hours) enteral nutrition in the Intensive Care Setting.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Confusion Assessment Method (CAM- ICU)
Time Frame: Day 1-14 after randomization or until ICU discharge
|
CAM ICU score (lowest score 0, highest score 7) • Cognitive function (MoCA- and MMST- Score) day 1, 7, 14 / ICU discharge |
Day 1-14 after randomization or until ICU discharge
|
|
• Montreal Cognitive Assessment (MoCA- Score)
Time Frame: Day 1-14 after randomization or until ICU- discharge
|
• Cognitive function (MoCA- Score) (lowest Score 0, highest Score 30)
|
Day 1-14 after randomization or until ICU- discharge
|
|
MMSE (Minimental State Examination)
Time Frame: Day 1-14 after randomization or until ICU discharge
|
MMSE Score (lowest Score 0, highest Score 30)
|
Day 1-14 after randomization or until ICU discharge
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of ventilation
Time Frame: From day of randomization until ICU discharge up to 1 month
|
Length of invasive and noninvasive ventilation
|
From day of randomization until ICU discharge up to 1 month
|
|
Length of ICU- and Hospital stay
Time Frame: From day of randomization until hospital discharge up to 6 months
|
Length of ICU- and Hospital stay
|
From day of randomization until hospital discharge up to 6 months
|
|
30-day mortality
Time Frame: From day of randomization up until 30 days
|
Mortality at day 30 after ICU admission
|
From day of randomization up until 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bernd W Böttiger, Prof, University Hospital Cologne
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-1398_2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.